Prognosis and treatment of desquamative inflammatory XXXX .

@entity1 @entity32 @entity701 @entity365 @entity3402
OBJECTIVE: Desquamative inflammatory @entity365 is a clinical syndrome frequently unrecognized, characterized by vaginal rash and purulent discharge. We describe @entity1 outcomes and treatment at follow-up in a case series of 98 @entity1 diagnosed with this syndrome. METHODS: We performed a chart review of 130 @entity1 diagnosed with desquamative inflammatory @entity365 between 1996 and 2007 in a referral university-based @entity365 clinic. Clinical findings, laboratory findings, and treatment were documented during the first 12 months and at 2 and 4 years. RESULTS: Of the 98 @entity1 reviewed, 97 were white; mean age was 48.6 years (plus or minus 10.2 years), and 50% were postmenopausal. All @entity1 were symptomatic with vaginal @entity32 and 72% had vestibular findings. Treatment with topical 2% @entity3402 (54%) or 10% @entity701 (46%) dramatically relieved symptoms within 3 weeks (median) in 86% of @entity1 . Treatment was discontinued (median 8 weeks) in 53 @entity1 experiencing clinical remission accompanied by normal wet mount appearance; however, 17 (32%) relapsed within 6 weeks. At 1 year, cure was achieved in 25 @entity1 (26%), 57 (58%) were asymptomatic but remained dependent on maintenance treatment, and 16 (16%) were partially controlled only. A favorable initial response to therapy was associated with positive clinical prognosis by 20 weeks of follow-up (P=.01). CONCLUSION: Desquamative inflammatory @entity365 is a chronic inflammatory process involving both vagina and vestibule, occurring almost exclusively in white @entity1 , that responds well to topical anti-inflammatory therapy, although long-term maintenance therapy frequently is required. LEVEL OF EVIDENCE: III.
